Shionogi & Co., Ltd. (SGIOY)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Shionogi & Co., Ltd. (SGIOY) trades at $8.58. Shionogi & Co. , Ltd. is a Japanese pharmaceutical company focused on researching, developing, manufacturing, and distributing innovative medicines. Market cap: $14.60B, Sector: Healthcare.
Last analyzed: Mar 18, 2026Analyst Coverage for SGIOY: SGIOY does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates SGIOY against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
SGIOY: 1/1 perspectives are bearish.
Shionogi & Co., Ltd. (SGIOY) Healthcare & Pipeline Overview
Shionogi & Co., Ltd., a Japanese pharmaceutical company established in 1878, specializes in developing and distributing pharmaceuticals, diagnostic reagents, and medical devices, with a focus on infectious diseases and central nervous system disorders, competing within the global specialty and generic drug market and demonstrating a strong profit margin of 41.9%.
What Is the Investment Thesis for SGIOY?
Shionogi & Co., Ltd. presents a compelling investment case based on its focus on innovative pharmaceuticals and strong profitability, indicated by a 41.9% profit margin. Key value drivers include the continued success of its flagship products like Fetroja and Xofluza, along with the potential of its extensive drug pipeline targeting various therapeutic areas. Upcoming catalysts include the advancement of drugs like Zuranolone for depression and S-723595 for NASH through clinical trials. However, investors should be aware of risks associated with pharmaceutical development, such as clinical trial failures and regulatory hurdles. The company's P/E ratio of 15.15 suggests a reasonable valuation relative to its earnings.
Based on FMP financials and quantitative analysis
SGIOY Key Highlights
- Market capitalization of $18.62 billion reflects Shionogi's significant presence in the pharmaceutical industry.
- Profit margin of 41.9% demonstrates strong profitability and efficient operations.
- Gross margin of 84.3% indicates effective cost management in pharmaceutical production.
- Dividend yield of 1.79% provides a steady income stream for investors.
- Beta of 0.02 suggests low volatility compared to the overall market.
Who Are SGIOY's Competitors?
Who Are SGIOY's Competitors?
SGIOY is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| ALBHF Alibaba Health Information Technology Limited | $0.48 | +0.00% | 8B | 45 |
| BIOVF Swedish Orphan Biovitrum AB (publ) | $47.35 | -0.26% | $16.38B | 56 |
| BMXMF bioMérieux S.A. | $84.08 | -0.00% | $9.92B | 52 |
| CHJTF CSPC Pharmaceutical Group Limited | $1.05 | +0.00% | $11.98B | 50 |
| CSPCY CSPC Pharmaceutical Group Limited | $3.53 | -3.42% | $10.17B | 48 |
| ALVO Alvotech | $4.16 | -1.89% | 2B | 69 |
| MPXOF MPX International Corporation | $0.00 | +0.00% | 2K | 68 |
| AERI Aerie Pharmaceuticals, Inc. | $15.25 | +0.00% | 68 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are SGIOY's Key Strengths?
- Strong pipeline of drugs in development.
- Established presence in the Japanese pharmaceutical market.
- High profit margin and gross margin.
- Expertise in infectious disease treatments.
What Are SGIOY's Weaknesses?
- Reliance on a limited number of key products.
- Geographic concentration in Japan.
- Exposure to patent expiration risks.
- Dependence on partnerships for certain drug development programs.
What Could Drive SGIOY Stock Higher?
- Clinical trial results for Zuranolone in depression expected in Q4 2026.
- Regulatory approval decisions for S-723595 in NASH anticipated in 2027.
- Continued revenue growth from key products like Fetroja and Xofluza.
- Expansion of strategic collaborations and partnerships.
- Progress in the development of COVID-19 treatments.
What Are the Key Risks for SGIOY?
- Failure of clinical trials for key drug candidates.
- Regulatory delays or rejection of drug approvals.
- Increasing competition from generic drug manufacturers.
- Patent expiration risks for key products.
- Product liability claims and litigation.
What Are the Growth Opportunities for SGIOY?
- Expansion of Infectious Disease Portfolio: Shionogi has a significant opportunity to expand its infectious disease portfolio, particularly with its existing drugs like Fetroja and Xofluza. The global market for infectious disease treatments is projected to reach $250 billion by 2028, driven by increasing antibiotic resistance and emerging infectious diseases. Shionogi's ongoing research and development efforts in this area could lead to the introduction of new and innovative treatments, capturing a larger share of this growing market.
- Development of Central Nervous System (CNS) Therapies: Shionogi is actively developing therapies for CNS disorders, including depression and neuropathic pain. The CNS therapeutics market is expected to reach $150 billion by 2027, fueled by the increasing prevalence of mental health disorders and neurological conditions. Successful development and commercialization of drugs like Zuranolone could significantly contribute to Shionogi's revenue growth.
- Advancement of NASH Treatment: Shionogi's development of S-723595 for NASH (nonalcoholic steatohepatitis) represents a significant growth opportunity. The NASH market is projected to reach $35 billion by 2030, driven by the rising prevalence of obesity and diabetes. If S-723595 proves to be an effective treatment, Shionogi could become a major player in this rapidly expanding market.
- Strategic Collaborations and Partnerships: Shionogi's existing collaborations with Nagasaki University and other institutions provide a platform for developing new antimalarial drugs and other innovative therapies. By forming strategic partnerships with research institutions and other pharmaceutical companies, Shionogi can leverage external expertise and resources to accelerate its drug development pipeline and expand its market reach.
- Geographic Expansion: While Shionogi primarily operates in Japan, there is a significant opportunity to expand its geographic presence, particularly in North America and Europe. By obtaining regulatory approvals for its key products in these regions and establishing distribution networks, Shionogi can tap into larger markets and diversify its revenue streams. This expansion could be achieved through partnerships or direct investment in overseas operations.
What Opportunities Does SGIOY Have?
- Expansion into new therapeutic areas.
- Geographic expansion into North America and Europe.
- Strategic acquisitions of complementary businesses.
- Development of innovative drug delivery systems.
What Threats Does SGIOY Face?
- Increasing competition from generic drug manufacturers.
- Stringent regulatory requirements and approval processes.
- Patent litigation and intellectual property disputes.
- Economic downturns and healthcare spending cuts.
What Are SGIOY's Competitive Advantages?
- Strong research and development capabilities.
- Proprietary drug formulations and patents.
- Established distribution network in Japan.
- Expertise in infectious disease treatments.
What Does SGIOY Do?
Shionogi & Co., Ltd., founded in 1878 as Shionogi Shoten Co., Ltd. and renamed in 1943, is a Japanese pharmaceutical company headquartered in Osaka. The company is dedicated to the research, development, manufacture, and distribution of pharmaceuticals, diagnostic reagents, and medical devices. Shionogi's product portfolio includes treatments for infectious diseases, pain management, and central nervous system disorders. Key products include Fetroja, a treatment for multidrug-resistant gram-negative bacterial infections; Xofluza, an influenza virus drug; and Tivicay, used in HIV treatment. The company also develops treatments for opioid-induced constipation (Symproic) and has a pipeline of drugs targeting inflammatory pain, neuropathic pain, insomnia, and obesity. Shionogi has collaboration agreements with institutions like Nagasaki University to develop antimalarial drugs. The company operates primarily in Japan, with a global presence through its innovative pharmaceutical products.
What Products and Services Does SGIOY Offer?
- Researches and develops pharmaceutical products.
- Manufactures pharmaceutical drugs and diagnostic reagents.
- Distributes pharmaceuticals and medical devices.
- Focuses on treatments for infectious diseases.
- Develops therapies for pain management.
- Creates drugs for central nervous system disorders.
- Offers diagnostic test kits for COVID-19.
How Does SGIOY Make Money?
- Develops and patents innovative pharmaceutical products.
- Generates revenue through the sale of prescription drugs.
- Partners with research institutions to discover new drug candidates.
- Commercializes and distributes its products globally.
What Industry Does SGIOY Operate In?
Shionogi & Co., Ltd. operates within the global pharmaceutical industry, which is characterized by intense competition, stringent regulatory requirements, and high research and development costs. The industry is driven by innovation, with companies constantly seeking to develop new and improved treatments for various diseases. Shionogi's focus on specialty and generic drugs positions it within a segment that is experiencing growth due to aging populations and increasing healthcare needs. Competitors include companies like ALBHF, BIOVF, BMXMF, CHJTF, and CSPCY, all vying for market share in various therapeutic areas.
Who Are SGIOY's Key Customers?
- Hospitals and clinics.
- Pharmacies and drug stores.
- Healthcare providers.
- Patients requiring prescription medications.
SGIOY Financials
SGIOY Latest News
-
Stocks That Hit 52-Week Lows On Tuesday
· Mar 24, 2020
-
Stocks That Fell Through 52-Week Lows Wednesday
· Aug 7, 2019
SGIOY Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for SGIOY.
Price Targets
Wall Street price target analysis for SGIOY.
SGIOY MoonshotScore
What does this score mean?
The MoonshotScore rates SGIOY's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Who Are SGIOY's Competitors?
Leadership: Isao Teshirogi
CEO
Isao Teshirogi serves as the CEO of Shionogi & Co., Ltd. His career spans several decades in the pharmaceutical industry, with a focus on research and development. He has held various leadership positions within Shionogi, contributing to the company's strategic direction and product development initiatives. Teshirogi's expertise lies in driving innovation and expanding Shionogi's global presence.
Track Record: Under Isao Teshirogi's leadership, Shionogi has achieved significant milestones in drug development and commercialization, including the successful launch of key products like Xofluza and Fetroja. He has overseen strategic collaborations and partnerships that have strengthened Shionogi's pipeline and expanded its market reach. Teshirogi's focus on innovation has positioned Shionogi as a leader in the treatment of infectious diseases and other therapeutic areas.
Shionogi & Co., Ltd. ADR Information Unsponsored
An American Depositary Receipt (ADR) is a certificate representing shares of a foreign company trading on U.S. stock exchanges. SGIOY is an ADR representing shares of Shionogi & Co., Ltd., allowing U.S. investors to invest in the company without directly dealing with foreign markets. The ADR is denominated in U.S. dollars, simplifying transactions.
- Home Market Ticker: Tokyo Stock Exchange, Japan
- ADR Level: 1
- ADR Ratio: 1:1
- Home Market Ticker: SGIO
SGIOY OTC Market Information
The OTC Other tier represents the lowest tier of the over-the-counter (OTC) market. Companies in this tier often have limited or no financial disclosure requirements and may not meet the listing standards of major exchanges like the NYSE or NASDAQ. Investing in OTC Other stocks carries higher risks due to the potential for limited information and regulatory oversight.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited financial disclosure.
- Potential for fraud or manipulation.
- Low trading volume and liquidity.
- Lack of regulatory oversight.
- Higher price volatility.
- Verify the company's registration and legal status.
- Review available financial information, if any.
- Assess the company's business model and competitive landscape.
- Research the management team and their track record.
- Understand the risks associated with investing in OTC stocks.
- Consider seeking professional financial advice.
- Monitor news and developments related to the company.
- Established history as a pharmaceutical company.
- Presence of approved pharmaceutical products.
- Partnerships with reputable research institutions.
- Publication of scientific research and clinical trial data.
- Compliance with applicable regulations and standards.
What Investors Ask About Shionogi & Co., Ltd. (SGIOY) — Healthcare
What does Shionogi & Co., Ltd. do?
Shionogi & Co., Ltd. is a research-driven pharmaceutical company focused on developing and commercializing innovative medicines. The company's core business involves the discovery, development, manufacture, and marketing of pharmaceutical products, diagnostic reagents, and medical devices. Shionogi specializes in therapeutic areas such as infectious diseases, pain management, and central nervous system disorders, with key products including Fetroja, Xofluza, and Tivicay. The company operates primarily in Japan, with a growing global presence through strategic partnerships and product commercialization efforts.
What do analysts say about SGIOY stock?
Analyst coverage of SGIOY is limited due to its OTC listing and ADR Level 1 status. Available research suggests a neutral outlook, with focus on Shionogi's pipeline potential and existing product performance. Key valuation metrics include the company's P/E ratio of 15.15 and dividend yield of 1.79%. Growth considerations center around the successful development and commercialization of new drugs and expansion into new markets. Investors should conduct their own due diligence and consider the risks associated with OTC investments.
What are the main risks for SGIOY?
The main risks for SGIOY include the inherent uncertainties of pharmaceutical research and development, such as clinical trial failures and regulatory hurdles. The company also faces competition from generic drug manufacturers and patent expiration risks for its key products. Additionally, SGIOY's OTC listing and ADR Level 1 status expose investors to risks associated with limited financial disclosure, low liquidity, and potential price volatility. Investors should carefully assess these risks before investing in SGIOY.
What are the key factors to evaluate for SGIOY?
Evaluating SGIOY involves reviewing fundamentals, analyst consensus, and risk factors. Key strength: Strong pipeline of drugs in development. Primary risk to monitor: Failure of clinical trials for key drug candidates. This is not financial advice.
How frequently does SGIOY data refresh on this page?
SGIOY prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven SGIOY's recent stock price performance?
Recent price movement in Shionogi & Co., Ltd. (SGIOY) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Strong pipeline of drugs in development. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Should investors consider SGIOY overvalued or undervalued right now?
Determining whether Shionogi & Co., Ltd. (SGIOY) is overvalued or undervalued requires examining multiple metrics. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.
What research should beginners do before buying SGIOY?
Before investing in Shionogi & Co., Ltd. (SGIOY), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Limited analyst coverage due to OTC listing.
- Financial data based on available public information.